ECSP20076576A - Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas - Google Patents

Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas

Info

Publication number
ECSP20076576A
ECSP20076576A ECSENADI202076576A ECDI202076576A ECSP20076576A EC SP20076576 A ECSP20076576 A EC SP20076576A EC SENADI202076576 A ECSENADI202076576 A EC SENADI202076576A EC DI202076576 A ECDI202076576 A EC DI202076576A EC SP20076576 A ECSP20076576 A EC SP20076576A
Authority
EC
Ecuador
Prior art keywords
binding proteins
receptor binding
cannabinoid receptor
proteins type
type
Prior art date
Application number
ECSENADI202076576A
Other languages
English (en)
Inventor
Nikolai Suslov
Antara Banerjee
Kacey Sachen
Robert Hoey
Andrea Fanjul
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP20076576A publication Critical patent/ECSP20076576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Proteínas de unión al CB1 no naturales, aisladas, modificadas genéticamente que incluyen anticuerpos anti-CB1 o un fragmento de unión al antígeno de los mismos. Las proteínas de unión al CB1 son de utilidad en el tratamiento y diagnóstico de condiciones, enfermedades y trastornos mediados por CB1.
ECSENADI202076576A 2018-04-30 2020-11-27 Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas ECSP20076576A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664882P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
ECSP20076576A true ECSP20076576A (es) 2021-12-30

Family

ID=67396963

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202076576A ECSP20076576A (es) 2018-04-30 2020-11-27 Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas

Country Status (21)

Country Link
US (3) US12202901B2 (es)
EP (1) EP3787746A1 (es)
JP (3) JP7431750B2 (es)
KR (1) KR102992188B1 (es)
CN (1) CN112218684A (es)
AR (1) AR114436A1 (es)
AU (1) AU2019264029B2 (es)
BR (1) BR112020022035A2 (es)
CA (1) CA3098416A1 (es)
CL (1) CL2020002793A1 (es)
CO (1) CO2020014681A2 (es)
EA (1) EA202092593A1 (es)
EC (1) ECSP20076576A (es)
IL (1) IL278276B2 (es)
MA (1) MA52504A (es)
MX (1) MX2020011498A (es)
PE (1) PE20210419A1 (es)
PH (1) PH12020551805A1 (es)
SG (1) SG11202010388SA (es)
TW (1) TWI882957B (es)
WO (1) WO2019211665A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7431750B2 (ja) 2018-04-30 2024-02-15 武田薬品工業株式会社 カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用
AU2023249518A1 (en) * 2022-04-04 2024-10-17 Bird Rock Bio Sub, Inc. Prediction and treatment of fast progressing renal disease
EP4534672A1 (en) 2022-06-03 2025-04-09 Shionogi & Co., Ltd Antibody that binds to cannabinoid type 1 receptors
EP4539845A1 (en) * 2022-06-17 2025-04-23 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Peripheralization of centrally-acting cannabinoid-1 receptor antagonists by nanoparticles for the treatment metabolic related conditions
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途
WO2025257151A1 (en) * 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating ciliopathies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
WO2005023232A2 (en) 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
CA2915386A1 (en) * 2013-06-26 2014-12-31 Amgen Inc. Cb1 receptor antigen-binding proteins and uses thereof
KR102731863B1 (ko) 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
US10277406B1 (en) * 2014-09-05 2019-04-30 Digicert, Inc. Authentication process for issuing sequence of short-lived digital certificates
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
CA3000167A1 (en) * 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
JP7431750B2 (ja) 2018-04-30 2024-02-15 武田薬品工業株式会社 カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用

Also Published As

Publication number Publication date
US20210198358A1 (en) 2021-07-01
EP3787746A1 (en) 2021-03-10
US20220396620A1 (en) 2022-12-15
CO2020014681A2 (es) 2020-12-10
IL278276B1 (en) 2026-02-01
JP2024059646A (ja) 2024-05-01
EA202092593A1 (ru) 2021-02-12
PH12020551805A1 (en) 2021-07-26
MX2020011498A (es) 2021-01-29
US20250250341A1 (en) 2025-08-07
IL278276A (es) 2020-12-31
US11746155B2 (en) 2023-09-05
CL2020002793A1 (es) 2021-02-12
JP2026076162A (ja) 2026-05-11
US12202901B2 (en) 2025-01-21
JP7798931B2 (ja) 2026-01-14
KR102992188B1 (ko) 2026-07-15
PE20210419A1 (es) 2021-03-08
JP2021525059A (ja) 2021-09-24
WO2019211665A1 (en) 2019-11-07
TWI882957B (zh) 2025-05-11
KR20210005051A (ko) 2021-01-13
AU2019264029A1 (en) 2020-11-19
TW202003549A (zh) 2020-01-16
CA3098416A1 (en) 2019-11-07
SG11202010388SA (en) 2020-11-27
CN112218684A (zh) 2021-01-12
MA52504A (fr) 2021-04-28
IL278276B2 (en) 2026-06-01
AU2019264029B2 (en) 2026-06-04
BR112020022035A2 (pt) 2021-02-02
JP7431750B2 (ja) 2024-02-15
AR114436A1 (es) 2020-09-02

Similar Documents

Publication Publication Date Title
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
CL2019001434A1 (es) Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946)
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
MX2020003132A (es) Anticuerpos anti-ctla4 y usos de los mismos.
MX2017010919A (es) Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
CO2021008218A2 (es) Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso
CO2021008204A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso
PE20170258A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MY202687A (en) Pharmaceutical chimeric receptor composition and method thereof
EA202192488A1 (ru) Антитела против tsg-6 и их применения
JOP20210300A1 (ar) أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر
CO2019002550A2 (es) Anticuerpos anti-gm-csf y usos de los mismos
JOP20220068A1 (ar) بروتينات اندماج nkg2d واستخداماتها
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
JOP20210339A1 (ar) أجسام مضادة لـ angpt2
AR133072A2 (es) Anticuerpos aislados o fragmentos aislados de unión a antígeno de los mismos que se unen al receptor de leptina humana (lepr) y activan la señalización lepr
EA202090333A1 (ru) Фармацевтические комбинации, содержащие антитело к bst1 и аналог цитидина